US Stock MarketDetailed Quotes

ALNY Alnylam Pharmaceuticals

Watchlist
  • 240.550
  • +4.600+1.95%
Close Jan 8 16:00 ET
  • 240.550
  • 0.0000.00%
Post 20:01 ET
31.03BMarket Cap-91.81P/E (TTM)

Alnylam Pharmaceuticals Key Stats

Alnylam Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 8 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 549.563M--
--2024/Q4-- / 579.285M--
Oct 31, 20242024/Q3500.919M / 527.024M--
Aug 1, 20242024/Q2659.825M / 444.155M--
May 2, 20242024/Q1494.333M / 426.730M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 549.563M--
--2024/Q4-- / 579.285M--
Oct 31, 20242024/Q3500.919M / 527.024M--
Aug 1, 20242024/Q2659.825M / 444.155M--
May 2, 20242024/Q1494.333M / 426.730M--

Unlock Free Earnings Estimates

Alnylam Pharmaceuticals Earnings Reports

Read more

Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Jan 8, 2025

Buy

  • Buy

    76.19%
  • Hold

    19.05%
  • Sell

    4.76%

Price Target

No Data